Australian researchers find key 'go-betweeen' in heart disease

Medical researchers at the University of New South Wales (UNSW) - Australia, have shed light on a little-known mechanism involved in the thickening of arteries, a process associated with heart disease.

“Essentially we’ve uncovered a complex network of how one bad guy regulates another bad guy,” said Professor Levon Khachigian, of the Centre for Vascular Research (CVR) at UNSW. “We’ve also found a key to stopping this Mafioso network.”

Arteries thicken when tiny molecules are increased in blood vessels. These are known as ‘growth factors’, which make the space in the arteries narrower and make it harder for blood to pass through.

The team’s research focuses on one of four parts that make up a certain growth factor family known as PDGF. The work relates to the D chain of that growth factor.

“Our investigations have found that a key peptide hormone called angiotensin controls the expression of an important part of PDGF,” said Professor Khachigian.

“Angiotensin has long been implicated in cardiovascular ailments like high blood pressure, restenosis and atherosclerosis," he said. "Angiotensin uses a couple of 'middle men' in the cell to jack up levels of PDGF D chain".

"These 'go betweens' are crucial to angiotensin's mode of action," he said. "If we take out these middle men (actually called transcription factors) we can greatly limit production of the growth factor, which is the result we would hope to see clinically."

“Our findings will provide future opportunities to tease out more specific inhibitors of growth factor production in order to reduce the incidence of common vascular disorders.”

This is the first time PDGF D control has been studied at this molecular level.

The paper Inducible Platelet-Derived Growth Factor D-chain Expression by Angiotensin II and Hydrogen Peroxide Involves Transcriptional Regulation by Ets-1 and Sp1, has just been published in the influential international journal Blood.

http://www.unsw.edu.au

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients